You are here: Industry Insights > PD-(L)1

News List

Taking Over the "King of Medicine"? Chinese Enterprises Lead the Development of PD-(L)1/VEGF Bispecific Antibody Antitumor Drug Kevin
April 28, 2025
PD-(L)1 and VEGF (vascular endothelial growth factor) bispecific antibody therapies are considered a key direction for future tumor treatments, attracting increasing global interest due to their unique mechanism of action and promising clinical data.
How is the progress of China’s domestically produced PD-(L)1 “going global”? Yefenghong/PharmaSources
November 23, 2023
Recently, Coherus BioSciences announced that the FDA has approved the launch of PD-1 antibody toripalimab (marketed jointly by Junshi Biosciences and Coherus) for use in combination with gemcitabine/cisplatin as a first-line treatment for advanced recurre
Alphamab Oncology Announces First Patient Dosed in the Pivotal Clinical Study of KN046 for the Treatment of PD-(L)1 Refractory Advanced NSCLC prnasia
October 29, 2021
Alphamab Oncology (stock code: 9966.HK) announced, a pivotal clinical study of PD-L1/CTLA-4 bispecific antibody KN046 in China (ENREACH-LUNG-02) recently completed the first drug administration.
7 anti-PD-(L)1 antibodies in Phase III clinical trials: lung cancer is still an important indication competed for PharmaSources/1℃
March 06, 2019
Besides the above products mentioned, there are still 7 anti-PD-(L)1 antibodies in Phase III clinical trials, and lung cancer is still one of the important indications the most companies lay out.
China has Entered the Era of Tumor Immunotherapy: Updates on the R&D Progress of Anti-PD-(L)1 Antibodies PharmaSources/1℃
March 06, 2019
2018 was the first year of the tumor immunotherapy in China. The new era of tumor immunotherapy has begun in China with the marketing of anti-PD-(L)1 antibodies represented by Opdivo, Keytruda, and Tuoyi, etc. in China.
BMS’ Opdivo to Become the First Anti-PD-(L)1 Antibody to Enter China Dopine
April 27, 2018
According to the latest clinical trial data of the CheckMate-078 (NCT02613507, CTR20150767) of Opdivo (nivolumab) conduc